Submit to Special Issue Submit Abstract to Special Issue Review for JPM Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "Neuromodulation in the Clinical Treatment of Psychiatric Disorders"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 1 December 2023 | Viewed by 5421

Share This Special Issue

Special Issue Editor

Dr. Wei Zheng

E-Mail Website
Guest Editor

Department of Psychiatry, the Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China
Interests: depression; neuromodulation; transcranial magnetic stimulation; transcranial direct current stimulation; ketamine; electroconvulsive therapy; systematic review; meta-analysis

Special Issue Information

Dear Colleagues,

Neuromodulation techniques, including transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), electroconvulsive therapy (ECT), theta burst stimulation (TBS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), vagus nerve stimulation (VNS) and deep brain stimulation (DBS), have been widely applied in the treatment of major psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia, in clinical practice. This Special Issue of the Journal of Personalized Medicine aims to highlight the current state of the science and showcase some of the latest findings in the field of neuromodulation in the clinical treatment of psychiatric disorders and will comprise original research articles, reviews, systematic reviews and meta-analyses.

Dr. Wei Zheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

depression
neuromodulation
transcranial magnetic stimulation
transcranial direct current stimulation
transcranial alternating current stimulation
ketamine/esketamine
electroconvulsive therapy
vagus nerve stimulation
deep brain stimulation
systematic review
meta-analysis

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Other

Open AccessEditor’s ChoiceArticle

Omega-3 Fatty Acids Supplementation in the Treatment of Depression: An Observational Study

and

J. Pers. Med. 2023, 13(2), 224; https://doi.org/10.3390/jpm13020224 - 27 Jan 2023

Cited by 2 | Viewed by 2482

Abstract

Depression is a common mood disorder characterized by persistent sadness and loss of interest. Research suggests an association between the inclusion of omega-3 fatty acids in the diet and a reduced risk for depression. The present study evaluated the effectiveness of omega-3 fatty acid supplements in alleviating depressive symptoms in patients with mild to moderate depression. A total of 165 patients suffering from mild to moderated depression were randomized to receive omega-3 fatty acid supplementation, an antidepressant (single agent), or a combination of an antidepressant and omega-3 fatty acid supplementation. The clinical features of depression were assessed using the Hamilton Depression Rating Scale (HDRS) during the follow-up period. A statistically significant improvement in depressive symptoms was observed from baseline to first, second and third follow-ups within each treatment arm as measured by HRDS scores (p = 0.00001). Further, the HDRS scores at the third follow-up were significantly lower in patients on combination therapy of omega-3 fatty acid supplement and antidepressants (arm-3) than the patients on the omega-3 fatty acid supplement alone (arm-1) [Q = 5.89; p = 0.0001] or the patients taking an antidepressant alone (arm 2) [Q = 4.36; p = 0.0068]. The combination of an omega-3 fatty acid supplement and an antidepressant elicited significantly higher improvement in depressive symptoms than the supplement or the antidepressant alone. Full article

(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)

Other

Jump to: Research

Open AccessBrief Report

A Systematic Review of Intermittent Theta Burst Stimulation for Neurocognitive Dysfunction in Older Adults with Schizophrenia

and

J. Pers. Med. 2023, 13(3), 485; https://doi.org/10.3390/jpm13030485 - 08 Mar 2023

Cited by 1 | Viewed by 712

Abstract

Objective: Neurocognitive dysfunction is thought to be one of the core clinical features of schizophrenia, and older adults with schizophrenia exhibited greater overall cognitive deficits than younger adults. The aim of this systematic review was to examine the neurocognitive effects of intermittent theta burst stimulation (iTBS) as an adjunctive treatment for older adults suffering from schizophrenia. Methods: Randomized double-blinded controlled trials (RCTs) investigating the neurocognitive effects of adjunctive active iTBS versus sham iTBS in older adults with schizophrenia were systematically identified by independent investigators searching Chinese and English databases. Results: Two double-blinded RCTs (n = 132) compared the neurocognitive effects of adjunctive active iTBS (n = 66) versus sham iTBS (n = 66) in patients that fulfilled the inclusion criteria of this systematic review and were analyzed. One RCT found significant superiority of active iTBS over sham iTBS in improving neurocognitive performance in older adults with schizophrenia. In the other RCT, the findings on the neurocognitive effects of iTBS as measured by three different measurement tools were inconsistent. The dropout rate was reported in the two RCTs, ranging from 3.8% (3/80) to 7.7% (4/52). Conclusion: There is preliminary evidence that adjunctive iTBS may have some beneficial effects in the treatment of neurocognitive function in older patients with schizophrenia. Future RCTs with larger sample sizes focusing on the neurocognitive effects of adjunctive iTBS in older adults with schizophrenia are warranted to verify these findings. Full article

(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)

► Show Figures

Figure 1

Open AccessBrief Report

Comparison of Efficacy and Safety of Magnetic Seizure Therapy and Electroconvulsive Therapy for Depression: A Systematic Review

and

J. Pers. Med. 2023, 13(3), 449; https://doi.org/10.3390/jpm13030449 - 28 Feb 2023

Viewed by 679

Abstract

Objectives: As a new physical therapeutic technique, magnetic seizure therapy (MST) has established efficacy in the treatment of depression with few cognitive side effects, and thus appears to be a potential alternative to electroconvulsive therapy (ECT). The findings of randomized controlled trials (RCTs) examining the efficacy and safety of MST versus ECT for depression are inconsistent. This systematic review of RCTs was designed with the aim of assessing the safety and efficacy of MST versus ECT for patients with depression. Methods: The WanFang, Chinese Journal Net (CNKI), EMBASE, PubMed, Cochrane Library, and PsycINFO databases were systematically searched by three independent investigators, from their inceptions to July 24, 2021. Results: In total, four RCTs (n = 86) were included and analyzed. Meta-analyses of study-defined response (risk ratio (RR) = 1.36; 95% CI = 0.78 to 2.36; p = 0.28; I² = 0%), study-defined remission (RR = 1.17; 95% CI = 0.61 to 2.23; p = 0.64; I² = 0%), and the improvement in depressive symptoms (standardized mean difference (SMD) = 0.21; 95% CI = −0.29 to 0.71; p = 0.42; I² = 0%) did not present significant differences between MST and ECT. Three RCTs evaluated the cognitive effects of MST compared with ECT using different cognitive measuring tools, but with mixed findings. Only two RCTs reported adverse drug reactions (ADRs), but these lacked specific data. Only one RCT reported discontinuation due to any reason. Conclusions: This preliminary study suggests that MST appears to have a similar antidepressant effect as ECT for depression, but mixed findings on adverse cognitive effects were reported. Full article

(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)

► Show Figures

Figure 1

Open AccessSystematic Review

Functional Activity in the Effect of Transcranial Magnetic Stimulation Therapy for Patients with Depression: A Meta-Analysis

Yongyan Deng

Wenyue Li

and

Bin Zhang

J. Pers. Med. 2023, 13(3), 405; https://doi.org/10.3390/jpm13030405 - 24 Feb 2023

Viewed by 1066

Abstract

Depression is a long-lasting mental disorder that affects more than 264 million people worldwide. Transcranial magnetic stimulation (TMS) can be a safe and effective choice for the treatment of depression. Functional neuroimaging provides unique insights into the neuropsychiatric effects of antidepressant TMS. In this meta-analysis, we aimed to assess the functional activity of brain regions caused by TMS for depression. A literature search was conducted from inception to 5 January 2022. Studies were then selected according to predetermined inclusion and exclusion criteria. Activation likelihood estimation was applied to analyze functional activation. Five articles were ultimately included after selection. The main analysis results indicated that TMS treatment for depression can alter the activity in the right precentral gyrus, right posterior cingulate, left inferior frontal gyrus and left middle frontal gyrus. In resting-state studies, increased activation was shown in the right precentral gyrus, right posterior cingulate, left inferior frontal gyrus and left superior frontal gyrus associated with TMS treatment. In task-related studies, clusters in the right middle frontal gyrus, left sub-gyrus, left middle frontal gyrus and left posterior cingulate were hyperactivated post-treatment. Our study offers an overview of brain activity changes in patients with depression after TMS treatment. Full article

(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Neuromodulation in the Clinical Treatment of Psychiatric Disorders"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (4 papers)

Research

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI